Polyclonal Antibody to B-Cell Leukemia/Lymphoma 2 (Bcl2)
| Code | Size | Price |
|---|
| PAA778Hu01-20ul | 20ul | £81.00 |
Quantity:
| PAA778Hu01-100ul | 100ul | £149.00 |
Quantity:
| PAA778Hu01-200ul | 200ul | £200.00 |
Quantity:
| PAA778Hu01-1ml | 1ml | £454.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
B-Cell CLL/Lymphoma 2
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
B-Cell Leukemia/Lymphoma 2
Reactivity:
Mu;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-3ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunofluorescence:5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://www.ncbi.nlm.nih.gov/pubmed/31505165; https://wwwnature.fenshishang.com/articles/s41598-021-02454-1; https://pubmed.ncbi.nlm.nih.gov/35398498/; https://sciencedirect.53yu.com/science/article/pii/S0161813X22001395;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant B-Cell Leukemia/Lymphoma 2 (Bcl2) | RPA778Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||